Document Detail

Bacillus cereus endophthalmitis following intravitreous bevacizumab injection.
MedLine Citation:
PMID:  18435343     Owner:  NLM     Status:  MEDLINE    
The first case of Bacillus cereus endophthalmitis following an intravitreous injection of bevacizumab is described. A 77-year-old man presented to a retina specialist with an active choroidal neovascularization related to age-related macular degeneration for which he received intravitreous bevacizumab (1.25 mg) and post-injection topical gatifloxacin. Eight hours later, the patient woke up with excruciating pain and a decline in vision associated with nausea and vomiting. A vitreous biopsy was performed that revealed B. cereus. Despite intravitreous injections of vancomycin and ceftazidime on day 1 and pars plana vitrectomy with repeat intravitreous injections on day 3, the eye did not recover light perception.
Andrew C Kopel; Petros E Carvounis; Eric R Holz
Related Documents :
1547973 - Outward permeability of the blood-retinal barrier.
2249163 - A miniaturized vitrectomy system for vitreous and retinal biopsy.
3763143 - Surgical management of idiopathic epiretinal membranes.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye     Volume:  39     ISSN:  1542-8877     ISO Abbreviation:  Ophthalmic Surg Lasers Imaging     Publication Date:    2008 Mar-Apr
Date Detail:
Created Date:  2008-04-25     Completed Date:  2008-04-29     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  101155780     Medline TA:  Ophthalmic Surg Lasers Imaging     Country:  United States    
Other Details:
Languages:  eng     Pagination:  153-4     Citation Subset:  IM    
Cullen Eye Institute, Baylor College of Medicine, 6560 Fannin, Houston, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*
Anti-Bacterial Agents / therapeutic use
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Bacillus cereus / isolation & purification*
Blindness / etiology
Ceftazidime / therapeutic use
Choroidal Neovascularization / drug therapy
Combined Modality Therapy
Drug Therapy, Combination
Endophthalmitis / diagnosis,  drug therapy,  microbiology*
Eye Infections, Bacterial / diagnosis,  drug therapy,  microbiology*
Gram-Positive Bacterial Infections / diagnosis,  drug therapy,  microbiology*
Injections / adverse effects*
Macular Degeneration
Vancomycin / therapeutic use
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity
Vitreous Body / microbiology
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Anti-Bacterial Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Vascular Endothelial Growth Factor A; 1404-90-6/Vancomycin; 2S9ZZM9Q9V/bevacizumab; 78439-06-2/Ceftazidime

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bilateral vision loss reveals occult pregnancy.
Next Document:  Hypotonous malignant glaucoma: aqueous misdirection with low intraocular pressure.